| Literature DB >> 35962594 |
Jens Becker1, Vincent Perreten2, Gertraud Schüpbach-Regula3, Dimitri Stucki1, Adrian Steiner1, Mireille Meylan1.
Abstract
OBJECTIVES: Antimicrobial drugs are frequently administered in veal calves, but investigations on associations with antimicrobial susceptibility of bacteria are scarce and convey partly contradictory findings. The aim of this study was to investigate associations of antimicrobial use (AMU) during the fattening period with antimicrobial susceptibility shortly before slaughter.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35962594 PMCID: PMC9525080 DOI: 10.1093/jac/dkac246
Source DB: PubMed Journal: J Antimicrob Chemother ISSN: 0305-7453 Impact factor: 5.758
Antimicrobial treatment incidence (TI) of 1864 treatments in defined daily doses (DDDs) per treated calf and year (TIDDD)[a] grouped by antimicrobial classes according to the method of the EMA
| Antimicrobial class |
| Total TIDDD | Calf level TIDDD per year | ||
|---|---|---|---|---|---|
| 25th percentile | median | 75th percentile | |||
| Tetracyclines | 593 | 19846.1 | 13.0 | 29.7 | 38.7 |
| Penicillins | 292 | 7481.3 | 17.1 | 25.0 | 32.1 |
| Macrolides | 372 | 5659.3 | 3.0 | 6.5 | 18.1 |
| Sulphonamides | 343 | 4947.3 | 8.2 | 12.8 | 17.8 |
| Diaminopyrimidines | 60 | 2462.6 | 29.8 | 38.9 | 45.3 |
| Phenicols | 111 | 1659.9 | 6.7 | 11.3 | 17.9 |
| Fluoroquinolones | 51 | 1181.7 | 3.7 | 13.2 | 26.4 |
| Aminoglycosides | 32 | 466.9 | 7.3 | 10.2 | 20.6 |
| Cephalosporins of third generation | 7 | 223.5 | 27.0 | 34.8 | 38.4 |
| Cephalosporins of fourth generation | 2 | 48.7 | 17.8 | 24.3 | 30.9 |
| Lincosamides | 1 | 3.8 | – | – | – |
For each antimicrobial class, the total number of treatments applied during the study period in the 38 study farms is presented (n), as well as the total TI of all treatments with a drug of the respective class (in decreasing order of total TIDDD).
Treatment incidences for individual calf treatments with antimicrobials of the respective class are provided including their 25th percentile, median and 75th percentile.
DDDs and standard weight extracted from: ‘Defined daily doses for animals (DDDvet) and defined course doses for animals (DCDvet): European Surveillance of Veterinary Antimicrobial Consumption (ESVAC), and Revised ESVAC reflection paper on collecting data on consumption of antimicrobial agents per animal species, on technical units of measurement and indicators for reporting consumption of antimicrobial agents in animals’ (www.ema.europa.eu).
Antimicrobial treatment incidence (TI) for 1864 treatments in defined daily doses (DDDs) per treated calf and year (TIDDD)[a] grouped by antimicrobial drug according to the method of the EMA
| Antimicrobial drug |
| Total TIDDD | Calf level TIDDD per year | ||
|---|---|---|---|---|---|
| 25th percentile | median | 75th percentile | |||
| Chlortetracycline | 309 | 12327.6 | 29.7 | 35.2 | 43.7 |
| Amoxicillin | 223 | 5992.3 | 19.0 | 27.1 | 32.6 |
| Doxycycline | 77 | 4138.1 | 25.0 | 30.4 | 75.7 |
| Sulfadimidine | 278 | 3626.0 | 7.8 | 11.9 | 16.1 |
| Oxytetracycline | 207 | 3380.4 | 6.7 | 9.3 | 20.8 |
| Trimethoprim | 60 | 2462.6 | 29.8 | 38.9 | 45.3 |
| Tulathromycin | 46 | 2215.9 | 25.1 | 27.2 | 33.0 |
| Spiramycin | 91 | 2014.4 | 15.6 | 17.0 | 20.3 |
| Florfenicol | 111 | 1659.9 | 6.7 | 11.3 | 17.9 |
| Procaine benzylpenicillin | 64 | 1392.1 | 12.0 | 17.9 | 28.7 |
| Tylosin | 222 | 1331.4 | 2.4 | 3.3 | 5.2 |
| Phthalylsulfathiazole | 56 | 1152.8 | 14.3 | 19.3 | 21.7 |
| Danofloxacin | 19 | 741.9 | 11.9 | 23.2 | 35.4 |
| Dehydrostreptomycin | 30 | 460.8 | 8.0 | 10.3 | 21.2 |
| Marbofloxacin | 31 | 424.7 | 1.9 | 7.4 | 20.3 |
| Ceftiofur | 7 | 223.5 | 27.0 | 34.8 | 38.4 |
| Tilmicosin | 13 | 97.6 | 6.2 | 7.4 | 8.6 |
| Sulfaguanidine | 3 | 81.2 | 0.5 | 0.5 | 40.4 |
| Amoxicillin + clavulanic acid | 3 | 79.9 | 7.9 | 8.9 | 36.5 |
| Cefquinome | 2 | 48.7 | 17.8 | 24.3 | 30.9 |
| Sulfadiazine | 3 | 40.2 | 4.1 | 5.0 | 18.4 |
| Sulfadoxine | 2 | 37.2 | 12.5 | 18.6 | 24.7 |
| Benzathine benzylpenicillin | 2 | 16.9 | 7.1 | 8.5 | 9.8 |
| Enrofloxacin | 1 | 15.1 | – | – | – |
| Sulfamethoxypyridazin | 1 | 9.9 | – | – | – |
| Lincomycin | 1 | 3.8 | – | – | – |
| Spectinomycin | 1 | 3.5 | – | – | – |
| Neomycin | 1 | 2.6 | – | – | – |
For each antimicrobial drug, the total number of treatments applied during the study period in the 38 study farms is presented (n), as well as the total TI of all treatments with a respective drug (in decreasing order of total TIDDD).
Treatment incidences for individual calf treatments with the respective drug are provided including their 25th percentile, median and 75th percentile.
See Table 1 for footnotes.
Figure 1.AMU in 38 veal-fattening operations, calculated as treatment incidence in defined daily doses (TIDDD) according to the method of the EMAa. Treatments were grouped by week of the fattening period, for antimicrobial classesb and overall use. aSee Table 1 for footnotes. bClasses with <10 treatments are not shown separately but appear in total TI. ◊Beginning of the fattening period (Week 1). Age of the calves was 4.6 (3.7/5.4) weeks (median, 25th/75th quantiles). *Timepoint of treatment: calves were treated at Week 4.4 (3.3/5.4) of the fattening period. ‡Timepoint of swabbing: calves were swabbed at Week 14.3 (12.3/16.9) of the fattening period. §Duration of the fattening period: 17.0 (15.0/19.0) weeks.
Proportion of isolates exhibiting a minimum of one resistance to an antimicrobial drug (=resistant isolate) plotted against the number of antimicrobial treatments for E. coli isolated from rectal swabs, as well as P. multocida and M. haemolytica isolated from nasopharyngeal swabs
| Number of antimicrobial treatments | Proportion of resistant isolates (%) | ||
|---|---|---|---|
|
|
|
| |
| 0 | 57.7 | 69.6 | 11.8 |
| 1 | 62.1 | 77.0 | 18.9 |
| >1 | 71.7 | 84.9 | 35.6 |
Number of antimicrobial treatments were categorized as none, one, or more than one antimicrobial treatment.
Results of the generalized linear models with a logit link function on individual isolates of E. coli isolated from rectal swabs and M. haemolytica isolated from nasopharyngeal swabs exhibiting at least one resistance to an antimicrobial in Swiss veal calves on 38 farms
| Predictors | OR | CI |
|
|---|---|---|---|
|
| |||
| (Intercept) | 1.41 | 1.04–1.93 | 0.029 |
| Number of treatments = 1 | 1.24 | 0.88–1.77 | 0.223 |
| Number of treatments >1 | 1.36 | 0.98–1.90 | 0.066 |
|
| |||
| (Intercept) | 4.91 | 2.12–11.36 | <0.001 |
| Number of treatments = 1 | 1.15 | 0.62–2.13 | 0.647 |
| Number of treatments >1 | 1.12 | 0.62–2.00 | 0.713 |
|
| |||
| (Intercept) | 0.12 | 0.07–0.22 | <0.001 |
| Number of treatments = 1 | 1.82 | 0.70–4.69 | 0.217 |
| Number of treatments >1 | 4.63 | 2.40–8.91 | <0.001 |
Number of antimicrobial treatments of calves carrying the respective isolate were categorized as no treatment (reference), one, or more than one antimicrobial treatment.
Results of the generalized linear models with a logit link function on E. coli isolated from rectal swabs and P. multocida isolated from nasopharyngeal swabs exhibiting resistance to a given antimicrobial drug when treated with a drug from the same antimicrobial class (homologous treatment) or not (heterologous treatment)
| Predictors | OR | CI |
|
|---|---|---|---|
|
| |||
| (Intercept) | 0.81 | 0.58–1.15 | 0.236 |
| Treatment(s) not containing tetracyclines | 1.05 | 0.74–1.48 | 0.803 |
| Treatment(s) containing tetracyclines | 1.86 | 1.34–2.58 | <0.001 |
|
| |||
| (Intercept) | 0.46 | 0.31–0.66 | <0.001 |
| Treatment(s) not containing penicillins | 1.14 | 0.83–1.57 | 0.420 |
| Treatment(s) containing penicillins | 1.66 | 1.11–2.48 | 0.014 |
|
| |||
| (Intercept) | 0.81 | 0.35–1.86 | 0.614 |
| Treatment(s) not containing aminoglycosides | 0.91 | 0.59–1.39 | 0.663 |
| Treatment(s) containing aminoglycosides | 3.66 | 0.88–15.21 | 0.074 |
Bacteria were isolated and treatments were recorded at the calf level on 38 Swiss veal calf farms.
Reference: ‘untreated’.